AROVELLA THERAPEUTICS LIMITED (ASX: ALA) — Company Overview, News & Financial Data
AROVELLA THERAPEUTICS LIMITED is an Australia-based biotechnology company focused on developing invariant Natural Killer T (iNKT) cell therapies for the treatment of cancer.
AROVELLA THERAPEUTICS LIMITED
AROVELLA THERAPEUTICS LIMITED is an Australia-based biotechnology company focused on developing invariant Natural Killer T (iNKT) cell therapies for the treatment of cancer. The company utilizes its proprietary CAR-iNKT cell therapy platform to create off-the-shelf, donor-derived therapeutics designed to target both blood cancers and solid tumors. Its lead research programs include CD19-targeted therapies for hematological malignancies and Claudin 18.2-targeted therapies for solid tumors such as gastric and pancreatic cancers. By combining chimeric antigen receptors with invariant T-cell receptor pathways and cytokine technology, the company develops multi-targeting cellular immunotherapies aimed at improving patient access and treatment outcomes.
Snapshot
Operations
Products and/or services of AROVELLA THERAPEUTICS LIMITED
- CD19-Targeting Cell Therapies: Development of allogeneic chimeric antigen receptor invariant Natural Killer T cell therapies directed against CD19 antigens for treating blood cancers, including non-Hodgkin lymphoma and B-cell leukemias in pediatric and adult patient populations.
- Claudin 18.2-Targeting Cell Therapies: Development of chimeric antigen receptor invariant Natural Killer T cell therapeutics engineered to target Claudin 18.2 expressers for the treatment of solid tumors, such as gastric and pancreatic cancers.
- Cytokine Enhancement Platform: Integration of membrane-anchored interleukin-12 cytokine technology into therapeutic cell constructs to improve cellular persistence, activation, and efficacy within immunosuppressive solid tumor microenvironments without systemic toxicity.
- Off-the-Shelf Allogeneic Cell Platform: Production of donor-derived invariant Natural Killer T cell therapies that do not induce graft-versus-host disease, providing scalable off-the-shelf cellular products for broader patient access compared to autologous treatments.
- CD1d-Mediated Dual-Targeting Platform: Utilization of invariant T-cell receptors to bind lipid antigens presented by CD1d molecules on tumor cells, enabling dual-action cancer targeting alongside chimeric antigen receptor mechanisms.
- Innate Cytotoxic Pathway Platform: Activation of natural killer cell receptor pathways, including NKG2D, to provide secondary tumor-killing capabilities and destroy immunosuppressive cells within the tumor microenvironment independent of targeted receptors.